Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | PLAU | P00749 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 2/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | ANPEP | P15144 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9572509 | 0.78 | ALDH1A1 (0.33) | SIGMAR1PLAUIDO1TSHR | |
| SCHEMBL6721448 | 0.77 | SIGMAR1 (0.43) | SIGMAR1PLAUIDO1PDPK1ANPEP | |
| SCHEMBL6676676 | 0.75 | PLAU (0.45) | SIGMAR1PLAUIDO1PDPK1ANPEP | |
| SCHEMBL30724832 | 0.75 | SIGMAR1 (0.42) | SIGMAR1PLAUIDO1PDPK1 | |
| SCHEMBL5255259 | 0.75 | PLAU (0.45) | SIGMAR1PLAUIDO1PDPK1ANPEP | |
| SCHEMBL10780065 | 0.75 | SIGMAR1 (0.42) | SIGMAR1PLAUIDO1PDPK1 | |
| SCHEMBL44650 | 0.73 | SIGMAR1 (0.44) | SIGMAR1PLAUTSHRGRIN2BCYP11B2 | |
| SCHEMBL30160953 | 0.73 | SIGMAR1 (0.41) | SIGMAR1PLAUIDO1PDPK1ANPEP | |
| SCHEMBL28525701 | 0.73 | SIGMAR1 (0.41) | SIGMAR1PLAUIDO1PDPK1ANPEP | |
| SCHEMBL11129686 | 0.73 | SIGMAR1 (0.44) | SIGMAR1PLAUIDO1PDPK1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2875014-B1 | ANTI-MUCUS DRUGS AND USES THEREFOR | UNIV WASHINGTON (US) | 2017-11-29 | — | — | EP | disclosed |
| US-9187470-B2 | Anti-mucus drugs and uses therefor | WASHINGTON UNIVERSITY (US) | 2015-11-17 | — | — | US | disclosed |
| US-20150183777-A1 | ANTI-MUCUS DRUGS AND USES THEREFOR | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-07-02 | — | — | US | disclosed |
| EP-2875014-A2 | ANTI-MUCUS DRUGS AND USES THEREFOR | Washington University (US) | 2015-05-27 | — | — | EP | disclosed |
| WO-2014015056-A2 | ANTI-MUCUS DRUGS AND USES THEREFOR | WASHINGTON UNIVERSITY (US) | 2014-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150183777-A1 | ANTI-MUCUS DRUGS AND USES THEREFOR | MAPK13, MAPK11, MUC1 | SIGMAR1 826/4885PLAU 1419/4885IDO1 3833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.